MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 10, Pages e108371
Publisher
Public Library of Science (PLoS)
Online
2014-10-08
DOI
10.1371/journal.pone.0108371
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunohistochemical Detection of Antitumor, Antimetastasis, and Antiangiogenesis Effects of a Vascular Endothelial Growth Factor Receptor 2 Kinase Inhibitor in an Orthotopic Breast Cancer Metastasis Model
- (2014) Bin Shi et al. JOURNAL OF HISTOTECHNOLOGY
- Cdks, cyclins and CKIs: roles beyond cell cycle regulation
- (2013) S. Lim et al. DEVELOPMENT
- Cyclin-dependent kinase inhibitor therapy for hematologic malignancies
- (2013) Prithviraj Bose et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
- (2013) John J Nemunaitis et al. Journal of Translational Medicine
- Emerging drug profile: cyclin-dependent kinase inhibitors
- (2013) James S. Blachly et al. LEUKEMIA & LYMPHOMA
- Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer
- (2013) Joe J. Stephenson et al. LUNG CANCER
- Dinaciclib (SCH727965) Inhibits the Unfolded Protein Response through a CDK1- and 5-Dependent Mechanism
- (2013) T. K. Nguyen et al. MOLECULAR CANCER THERAPEUTICS
- The Anti-Melanoma Activity of Dinaciclib, a Cyclin-Dependent Kinase Inhibitor, Is Dependent on p53 Signaling
- (2013) Brijal M. Desai et al. PLoS One
- Chemical Genomics Identifies Small-Molecule MCL1 Repressors and BCL-xL as a Predictor of MCL1 Dependency
- (2012) Guo Wei et al. CANCER CELL
- The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells
- (2012) A J Johnson et al. LEUKEMIA
- Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation
- (2012) Vassiliki E. Mpakou et al. LEUKEMIA RESEARCH
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Cyclin-dependent kinase inhibitors move into Phase III
- (2012) Malini Guha NATURE REVIEWS DRUG DISCOVERY
- Serine 162, an Essential Residue for the Mitochondrial Localization, Stability and Anti-Apoptotic Function of Mcl-1
- (2012) Luke W. Thomas et al. PLoS One
- Chemical-genetic analysis of cyclin dependent kinase 2 function reveals an important role in cellular transformation by multiple oncogenic pathways
- (2012) D. Horiuchi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models
- (2011) Georg Feldmann et al. CANCER BIOLOGY & THERAPY
- The Cyclin-Dependent Kinase Inhibitor SCH 727965 (Dinacliclib) Induces the Apoptosis of Osteosarcoma Cells
- (2011) W. Fu et al. MOLECULAR CANCER THERAPEUTICS
- Aven blocks DNA damage-induced apoptosis by stabilising Bcl-xL
- (2010) Ozgur Kutuk et al. EUROPEAN JOURNAL OF CANCER
- Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
- (2010) David Parry et al. MOLECULAR CANCER THERAPEUTICS
- Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines
- (2010) H Zhang et al. ONCOGENE
- Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia
- (2009) Rong Chen et al. BLOOD
- Triptolide functions as a potent angiogenesis inhibitor
- (2009) Ming-Fang He et al. INTERNATIONAL JOURNAL OF CANCER
- Triptolide-Induced Transcriptional Arrest Is Associated with Changes in Nuclear Substructure
- (2008) S. J. Leuenroth et al. CANCER RESEARCH
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models
- (2008) A. R. Shoemaker et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now